目的:靶向药物BCL-2抑制剂维奈克拉(venetoclax,VEN)的出现革新了急性髓系白血病(acute myeloid leukemia,AML)的治疗格局,尤其是对于老年或不适合强化疗的患者,其与去甲基化药物(hypomethyl-ating agents,HMAs)的联合方案在临床中得以广泛应用.我们对本中心近4年余VEN联合方案一线治疗在新诊断AML患者的真实世界应用情况进行回顾性研究,以期为临床实践提供参考.方法:回顾性收集和分析2019年8月至2024年2月首次接受VEN联合方案一线治疗的110例新诊断AML患者的临床资料,后续治疗策略由临床医生根据患者综合情况进行动态调整.结果:中位随访时间14.8(0.2～37.1)个月,中位VEN一线联合方案疗程数1(1～8)个,中位总抗AML治疗(非临床试验)疗程数3(1～10)个.应用人群:VEN一线联合方案已广泛应用于患者相关特征和AML疾病相关特征各异的新诊断AML患者,应用人群多伴有基础合并症(74.5％),且绝大多数在启动VEN联合治疗前存在≥3级血常规异常(98.2％).应用方案:诱导治疗以VEN+阿扎胞苷(azacitidine,AZA)为主(78.2％),29.1％的患者在仅接受诱导治疗后即失访或死亡,诱导治疗后继续治疗的患者中44.9％进行治疗策略调整,仅23.6％的患者持续接受≥4个疗程VEN+HMAs±FLT3抑制剂治疗.治疗反应:VEN 一线联合方案诱导治疗的复合完全缓解率(composite complete response,cCR)为80.2％,微小残留病(minimal residual disease,MRD)转阴率为69.2％;总队列中达到cCR或MRD转阴患者的中位总生存期(overall survival,OS)和中位无事件生存期(event-free survival,EFS)均显著优于未达到者[达到cCR组vs未达到 cCR 组中位 OS:37.1 vs 3.5 个月(P＜0.001),中位 EFS:14.8 vs 0.9 个月(P＜0.001);达到 MRD-组与未达到MRD-组中位OS:37.1 vs 3.5个月(P＜0.001),中位EFS:14.8 vs 1.3个月(P＜0.001)];总队列复发率为30.8％.安全性:总体耐受性较好,VEN+HMAs持续治疗的血液学毒性以第1个疗程为著,第2～4个疗程VEN+AZA组的3～4级血液学毒性和感染发生率总体低于VEN+地西他滨组,且VEN+AZA组随疗程增加呈下降趋势.结论:VEN联合方案一线治疗新诊断AML患者能够较快获得高治疗反应率,不良反应总体可耐受,且以第1个疗程为著.真实世界中VEN一线联合方案诱导后进行治疗策略调整情况常见,获得缓解或MRD转阴的患者生存获益显著.仍有相当比例的患者未能从VEN 一线联合方案中获益或复发,亟待寻求优化解决方案.
A single-center,real-world study of efficacy and safety of first-line venetoclax-based regimens in treating newly diagnosed acute myeloid leukemia
Objective:The advent of targeted drug BCL-2 inhibitor venetoclax(VEN)has revolutionized the treatment pattern of acute myeloid leukemia(AML),especially for elderly patients or those ineligible for intensive chemotherapy.Its combination regimens with hypomethylating agents(HMAs)have been widely used in clinical practice.We conducted a single-center,retrospective study on the real-world application of VEN-based first-line treatment in newly diagnosed AML patients over the past four years in aim of providing reference for clinical prac-tice.Methods:The clinical data of 110 newly diagnosed AML patients who received VEN first-line combination treatment for the first time from August 2019 to February 2024 were retrospectively analyzed.Results:The medi-an follow-up time was 14.8(0.2-37.1)months,with a median of 1(1-8)courses of first-line VEN combination therapy and a median of 3(1-10)courses of total treatment courses applied(clinical trials excluded).Application population:The VEN first-line combination therapy has been widely used in newly diagnosed AML patients with different patient-related and AML disease-related characteristics.The application population was often accompa-nied by underlying comorbidities(74.5％),and the vast majority had≥grade 3 blood routine tests abnormalities(98.2％)before initiating VEN combination therapy.Treatment regimens:VEN+azacitidine(AZA)was the main choice of induction therapy(78.2％).29.1％of patients were lost to follow-up or died after only receiving induction therapy.Among patients who continued treatment after induction therapy,44.9％underwent treatment strategy adjustments,and only 23.6％continued to receive≥4 courses of VEN+HMAs±FLT3 inhibitor treat-ment.Treatment response:The composite complete response rate(cCR)induced by VEN first-line combination therapy was 80.2％,and the rate of achieving negative minimal residual disease(MRD)was 69.2％.The median overall survival(OS)and median event-free survival(EFS)of patients who achieved cCR or MRD negative in the o-verall cohort were significantly better than those without cCR or MRD negative(the median OS of cCR vs non-cCR:37.1 vs 3.5 months[P＜0.001],the median EFS of cCR vs non-cCR:14.8 vs 0.9 months[P＜0.001];the median OS of MRD-vs non-MRD-:37.1 vs 3.5 months[P＜0.001],the median EFS of MRD-vs non-MRD-:14.8 vs 1.3 months[P＜0.001]).The overall recurrence rate was 30.8％.Safety:Overall toxicities were tolerable,and hematological toxicities of continuous treatment with VEN+HMAs were mainly observed in the first course.The incidence of grade 3-4 hematological toxicities and infection in the VEN+AZA group was generally lower than that in the VEN+decitabine group,and the VEN+AZA group showed a decreasing trend with the increase of treatment courses.Conclusion:VEN first-line combination therapy can achieve quick and high response in newly diagnosed AML patients,overall adverse events are tolerable,with the first course being the most notable.In real-world settings,it is common to adjust treatment strategies after first-line VEN induction therapy,patients who achieve remission or MRD negative can benefit from significant survival advantage.Howev-er,there is still a considerable proportion of patients who could not benefit from VEN-based first-line therapy or experienced relapse,optimized solutions are urgently needed.
NETL
NSTL
万方数据
